Host-directed therapies for infectious diseases: current status, recent progress, and future prospects (Q38795745)

6 September 2017

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects (English)

1 reference

6 September 2017

1 reference

1

1 reference

6 September 2017

10

0 references

Markus Maeurer

object named as

Markus Maeurer

13

0 references

Peter Mwaba

6

object named as

Peter Mwaba

1 reference

6 September 2017

12

Michael Hoelscher

1 reference

6 September 2017

8

Dorothy Yeboah-Manu

1 reference

6 September 2017

11

Esam Azhar

1 reference

6 September 2017

Martin Rao

2

1 reference

6 September 2017

Robert S Wallis

3

1 reference

6 September 2017

Stefan H E Kaufmann

4

1 reference

6 September 2017

Roxana Rustomjee

5

1 reference

6 September 2017

Cris Vilaplana

7

1 reference

6 September 2017

Jeremiah Chakaya

9

1 reference

6 September 2017

Host-Directed Therapies Network consortium

14

1 reference

6 September 2017

1 April 2016

1 reference

Lancet Infectious Diseases

6 September 2017

1 reference

6 September 2017

16

1 reference

6 September 2017

e47-63

1 reference

6 September 2017

4

1 reference

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Modulating immunity as a therapy for bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Effect of Acetylsalicylic Acid on Pulmonary Gas Exchange in Patients With Severe Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Statins and the risk of pneumonia: a population-based, nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Prior statin use is associated with improved outcomes in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The effect of statins on mortality in patients with bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Statin use and mortality within 180 days after bacteremia: A population-based cohort study*

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Effect of statin treatment on short term mortality after pneumonia episode: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Understanding the potential role of statins in pneumonia and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Glyburide reduces bacterial dissemination in a mouse model of melioidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Impact of initial antibiotic choice on mortality from pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Helicobacter pylori and gastric cancer: factors that modulate disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Helicobacter pylori induces increased expression of the vitamin d receptor in immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Sphingosine-1-phosphate Receptor Agonism Reduces Bordetella pertussis-mediated Lung Pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Novel therapies for the treatment of pertussis disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Rapid salvage treatment with virus-specific T cells for therapy-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

T-Cell Therapy: Options for Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Treatment of adenovirus infections in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Efficacy and safety of mipomersen sodium (Kynamro).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Management of patients with familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Treating influenza with statins and other immunomodulatory agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

How will physicians respond to the next influenza pandemic?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Cholesterol biosynthesis modulation regulates dengue viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Targeting host factors to treat West Nile and dengue viral infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Incretin-based therapies: viewpoints on the way to consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Coronaviruses - drug discovery and therapeutic options.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Delivery of host cell-directed therapeutics for intracellular pathogen clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Novel therapeutic and prevention approaches for schistosomiasis: review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The immune response in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Inflammation and tuberculosis: host-directed therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Metformin as adjunct antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

A high-throughput respirometric assay for mitochondrial biogenesis and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

IL-32 is a molecular marker of a host defense network in human tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

An enzyme that inactivates the inflammatory mediator leukotriene b4 restricts mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D3.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Cytotoxic therapy for severe avian influenza A (H5N1) infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Cytotoxic therapy for severe swine flu A/H1N1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Prospects for TIM3-Targeted Antitumor Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

LAG3 expression in active Mycobacterium tuberculosis infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Clinical blockade of PD1 and LAG3--potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Adalimumab treatment of life-threatening tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Interleukin-6 as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospectiv

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Interception of host angiogenic signalling limits mycobacterial growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Towards host-directed therapies for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Ten-year review of invasive pneumococcal diseases in children and adults from Uruguay: clinical spectrum, serotypes, and antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Immunomodulatory adjuvant therapy in severe community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Corticosteroids for acute bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

An African origin for the intimate association between humans and Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Towards an HIV-1 cure: measuring the latent reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Prospects for immune reconstitution in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Reversal of Latency as Part of a Cure for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Harnessing the biology of IL-7 for therapeutic application

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Progress in the development of vaccines for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8+ and CD4+ T Cells during Acute HCV Infection, Irrespective of Clinical Outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Insect-specific flaviviruses: a systematic review of their discovery, host range, mode of transmission, superinfection exclusion potential and genomic organization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Why are people with dengue dying? A scoping review of determinants for dengue mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Iron chelation therapy for iron loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Innate immunity against Leishmania infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

1 reference

7 January 2021

Advances in the Diagnosis of Human Schistosomiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

CD4+ T cell hyporesponsiveness after repeated exposure to Schistosoma mansoni larvae is dependent upon interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900078-5

7 January 2021

Anti-TNF therapy inhibits fever in cerebral malaria.

1 reference

12 December 2020

Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

1 reference

12 December 2020

Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model

1 reference

12 December 2020

HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome

1 reference

12 December 2020

Epidemiology of human African trypanosomiasis

1 reference

12 December 2020

Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria

1 reference

12 December 2020

10.1016/S1473-3099(16)00078-5

Identifiers

DOI

1 reference

6 September 2017

1 reference